Malignant Lymphomas And Hodgkin S Disease Experimental And Therapeutic Advances

Malignant lymphomas remain a fascinating research topic for clinicians as well as basic scientists. Rapidly increasing technical sophistication, ex panded knowledge and broader implications of new findings underline the need for a forum to integrate the latest developments in the multiple areas involved in the challenging study of lymphoid malignancies. This volume includes contributions of renowned experts and is based on a selection of papers presented at the Second International Conference on Malignant Lymphomas that was held in Lugano, Switzerland, in June 1984. Updated information is provided on various experimental fields including cell biolo gy, immunology, genetics and cell biochemistry. Particular attention has been given to special clinical entities such as the lymphomas associated with the Acquired Immune Deficiency Syndrome. Recent advances in the treat of Hodgkin's disease, ncin-Hodgkin's lymphomas and childhood lym ment phomas are highlighted with emphasis on growing experience with new therapeutic approaches including monoclonal antibodies and bone marrow transplantation. The contents of the volume reflect and translate numerous avenues of exploration. While there might be some unavoidable overlap, most appear essentially complementary. The intent of the Program Committee of the Second International Conference on Malignant Lymphomas was to promote further interactions between all those who are devoting major efforts to elucidate the nature of these diseases or their optimal therapy. This volume will hopefully amplify this objective. The Editors wish to thank the contributors for delivering the manuscripts on schedule.

Advances in Non-Hodgkin Lymphoma Research and Treatment: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Non-Hodgkin Lymphoma. The editors have built Advances in Non-Hodgkin Lymphoma Research and Treatment: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Non-Hodgkin Lymphoma in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Advances in Non-Hodgkin Lymphoma Research and Treatment: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

In the field of Hodgkin's lymphoma, many new data have been collected during the last decade both on the cell of origin of this disease and on more effective therapies to cure the majority of pa tients even in the advanced stages. Therefore, it seems to be justi fied to compile these new data in a special volume of Recent Re sults in Cancer Research. This volume summarizes the contribu tions presented at the First International Symposium on Hodgkin's Disease that took place in Cologne (FRG) on October 2-3, 1988. There is little doubt that the Hodgkin and Reed-Sternberg (H and RS) cells and their variants represent the malignant population in Hodgkin's lymphoma; however, there is still a fierce debate as to the possible cell of origin of Hand RS cells. Many of the problems confounding earlier research into this question were related to the difficulty or virtual impossibility, of obtaining purified populations of Hand RS cells. Most of the recent progress stems from the establishment of permanent cell lines of Hand RS cells in culture.

This authoritative text covers the full range of scientific and clinical developments that have occurred in the investigation and treatment of Hodgkin's disease and non-Hodgkin's lymphomas over recent years. Edited by a team of acknowledged experts in the field, with contributions from around the world, the text covers both current views and likely future developments, and covers a broad spectrum of clinical care, from the routine to the highly experimental. It will find a place on the shelf of any medical library and will be invaluable reading for all oncologists wanting a comprehensive update on state-of-the-art practice in the management of malignant lymphoma.

Fernando Cabanillas In 1993, Fisher et al. published the results of a randomized trial comparing three third-generation regimens against the classic CHOP combination. For several years, the oncology community had been convinced that the third generation regimens were clearly superior to CHOP. It came as a shock to many that there was no difference in outcome between the four arms of this clinical trial. The logical conclusion is that CHOP is as good as any of the other regimens tested in that study. Unfortunately, this excellent study has been misinterpreted by many as proving that there has not been any progress in the field of lymphoma during the last 20 years. Furthermore, it has led to a fatalistic attitude in the reasoning of many clinicians who feel that 'nothing works better than CHOP' and therefore that it is not worth testing new drugs or developing novel regimens. However, the process by which we move forward in the oncology field is seldom by dramatic breakthroughs. Frequently, what appears at first glance to be a breakthrough turns out later to be just a modest step forward. Several steps forward eventually add up to a major advance, but this advance goes unnoticed because of the slow nature of the process. In this volume, we have chosen to discuss several of these steps, which we feel are clearly making a positive impact on the field of lymphomas and which soon should make a major difference in therapeutic results.

This volume is intended to present an eclectic selection of informative reviews on aspects of the malignant lymphomas, including Hodgkin's disease. The choice of suitable review topics in this field is made hazardous by several facts. First, the growth of insight into basic mechanisms of lymphomagenesis is explosive, as is the expansion of our understanding of the need for precise morphologic classification of these diseases. Second, new therapeutic agents, cytotoxic and biologic, as well as new drug delivery strategies, are appearing with remarkable frequency. Finally, old "standard" approaches, such as the staging laparotomy for Hodgkin's disease, are being reconsidered and deserve attention in an up-to-date collection of papers. The 10 reviews presented here fall generally into three categories. First, the optimal diagnostic and therapeutic approaches to Hodgkin's disease are considered by Mark Leibenhaut, who reviews the status of the diagnostic staging laparotomy, and by Philip Bierman, who discusses his thoughts on the timing of high-dose treatment with bone marrow transplantation for this disease. There follow four reviews of current management of specific histologic subtypes of malignant lymphoma. First, Velasquez reviews prognostic factors in both intermediate and high grade lymphomas. Miller and Dahlberg review and update the Southwest Oncology Group experience in developing curative cytotoxic combination therapies for diffuse large-cell lymphomas. Lastly, optimal therapy for two kinds of high grade lymphoma are presented. Butler and Hainsworth describe the Vanderbilt experience with diffuse small noncleaved cell lymphoma and Picozzi reviews lymphoblastic lymphoma.

Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates